Physician profile
Sevan Evren
NPI 1043664758
$352.58
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.14 · 2020: $260.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $79.88 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $70.18 | 2020 | |
| Gilead Sciences, INC. | $53.84 | 2019-2020 | |
| Abbott Laboratories | $47.27 | 2020 | |
| Pfizer INC. | $38.81 | 2020 | |
| Novo Nordisk INC | $24.34 | 2019-2020 | |
| Allergan, INC. | $13.54 | 2019 | |
| Amarin Pharma, INC. | $13.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.34 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sevan Evren listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.